Lexaria Bioscience
LEXX
25 hedge funds and large institutions have $3.03M invested in Lexaria Bioscience in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 6 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
1.51% more ownership
Funds ownership: 6.75% → 8.26% (+1.5%)
7% less capital invested
Capital invested by funds: $3.25M → $3.03M (-$226K)
7% less funds holding
Funds holding: 27 → 25 (-2)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.13M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$40.1K |
| 4 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$37K |
| 5 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
+$24.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
G
GenTrust
Miami,
Florida
|
-$183K |
| 2 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$160K |
| 3 |
WG
Welch Group
Birmingham,
Alabama
|
-$73.2K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$56.8K |
| 5 |
HF
HRT Financial
New York
|
-$31K |
LEXX Hedge Fund Activity: Q4 2024 in Review
25 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q4 2024, worth a combined $3.03M — down 6.9% from $3.25M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LEXX and 5 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 8 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.13M. The largest seller was GenTrust, exiting entirely with an estimated $183K sold.
- 25 institutional investors held Lexaria Bioscience (LEXX) as of Q4 2024, down from 27 in Q3 2024.
- Funds reported $3.03M of Lexaria Bioscience stock for Q4 2024, down 6.9% quarter-over-quarter.
- 5 funds opened new Lexaria Bioscience positions in Q4 2024 and 6 closed out, a net change of -1 holder.
- The largest Lexaria Bioscience buyer in Q4 2024 was Armistice Capital, an estimated $1.13M added.
- The largest Lexaria Bioscience seller in Q4 2024 was GenTrust, an estimated $183K sold.
Based on aggregated 13F filings for Q4 2024.